Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to -$271000.0.

  • Harvard Bioscience's Change in Accured Expenses fell 183571.43% to -$271000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1000.0, marking a year-over-year increase of 10019.69%. This contributed to the annual value of -$1.8 million for FY2024, which is 24130.02% down from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's Change in Accured Expenses is -$271000.0, which was down 183571.43% from $302000.0 recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Change in Accured Expenses peaked at $2.7 million during Q1 2022, and registered a low of -$4.5 million during Q4 2021.
  • Its 5-year average for Change in Accured Expenses is -$250473.7, with a median of -$225000.0 in 2023.
  • As far as peak fluctuations go, Harvard Bioscience's Change in Accured Expenses skyrocketed by 66016.48% in 2024, and later crashed by 183571.43% in 2025.
  • Quarter analysis of 5 years shows Harvard Bioscience's Change in Accured Expenses stood at -$4.5 million in 2021, then skyrocketed by 121.99% to $980000.0 in 2022, then crashed by 122.96% to -$225000.0 in 2023, then crashed by 567.56% to -$1.5 million in 2024, then surged by 81.96% to -$271000.0 in 2025.
  • Its Change in Accured Expenses stands at -$271000.0 for Q3 2025, versus $302000.0 for Q2 2025 and $1.5 million for Q1 2025.